Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE) is a Healthcare company (Biotechnology) with a market capitalization of $775M. The Maz Rating grades it against the other companies in its sector.
Monte Rosa Therapeutics, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $9.07, Monte Rosa Therapeutics, Inc. trades at 11.0x sales and 1.9x book value. Over the last twelve months it generated about $71M of revenue and a net loss of $147M. It runs a gross margin of 97.1%, an operating margin of -214.5% and a net margin of -186.2%. It shows return on equity of -30.1%, return on invested capital of -23.6% and a free cash flow yield of -22.5%. On the balance sheet: a debt-to-equity ratio of 0.07 and a current ratio of 10.32. Over the past 52 weeks the share price ranged from $8.83 to $25.77, with a beta of 1.38.
Monte Rosa Therapeutics, Inc. does not currently pay a dividend.
10 Wall Street analyst ratings cover the stock: 8 Buy and 2 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Monte Rosa Therapeutics, Inc. is a biopharmaceutical company dedicated to pioneering novel, small-molecule precision medicines. Their core approach involves leveraging the body's inherent mechanisms to precisely eliminate therapeutically relevant proteins. Among their key initiatives is an oral molecular glue degrader designed to target GSPT1, a specific translational termination factor and degron-containing protein, with the aim of treating Myc-driven cancers. The company's pipeline further includes programs for CDK2 in ovarian, uterine, and breast cancers, alongside NEK7 for addressing a spectrum of inflammatory conditions such as Crohn's disease, neurodegenerative ailments, diabetes, and liver disease. Moreover, VAV1 is being explored as a target for autoimmune disorders, and BCL11A, a protein holding significant therapeutic relevance, is under investigation for hemoglobinopathies. Founded in 2019, Monte Rosa Therapeutics, Inc. operates from its headquarters in Boston, Massachusetts.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
No. As of September 2026, Monte Rosa Therapeutics, Inc. (GLUE) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 0.00% / 30% · (Cash+Inv) / Mkt Cap (36m) 55.3% / 30% · Interest income / Revenue 10.3% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 0.00% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 55.3% / 33% · Receivables / Mkt Cap (36m) 5.51% / 49% · Interest income / Revenue 10.3% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 0.00% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 55.3% / 33.33% · Receivables / Mkt Cap (24m) 5.51% / 33.33% · Interest income / Revenue 10.3% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 4.16% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 86.9% / 33.33% · Receivables / Avg Assets (4Q) 2.97% / 33.33% · Interest income / Revenue 10.3% / 5% | Fail |
| FTSE | Debt / Total Assets 0.00% / 33.33% · (Cash+ST Inv) / Total Assets 82.8% / 33.33% · (Cash+Recv) / Total Assets 91.1% / 33.33% · Interest income / Revenue 10.3% / 5% | Fail |
No. As of September 2026, Monte Rosa Therapeutics, Inc. (GLUE) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
No. Monte Rosa Therapeutics, Inc. is over the AAOIFI limit on (Cash+Inv) / Mkt Cap (36m) and Interest income / Revenue.
About 10.3% of each dividend: Monte Rosa Therapeutics, Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.